KMKeyla Milena Meneses

Keyla Milena Meneses

*This is an algorithmically generated author record based on publicly available information.

Keyla Milena Meneses has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Severe Pneumocystis jirovecii Pneumonia as the Sentinel Presentation of BENTA Disease: Case Report of a 3-Month-old Infant

    by Andrés Felipe Rubio-Duarte, María Paula Garcés-Rodríguez, Alexandra Hurtado-Ortiz, Mario Javier Forero-Manzano, José Antonio Vargas-Soler, Keyla Meneses-Silvera

    Pneumocystis jirovecii can cause severe pneumonia in HIV-negative infants with underlying immunodeficiency. We report an infant with prior acute respiratory distress syndrome and recurrent infections unresponsive to antibiotics. Persistent interstitial opacities led to immunologic testing, revealing T-cell lymphopenia and a CARD11 mutation. Respiratory polymerase chain reaction confirmed P. jirovecii . Treatment with trimethoprim–sulfamethoxazole and intravenous immunoglobulin led to recovery.

  • Everolimus for severe arrhythmias in tuberous sclerosis complex related cardiac rhabdomyomas

    by María P. Silva‐Sánchez, Jorge L. Alvarado‐Socarras, Javier Castro‐Monsalve, Keyla Milena Meneses, Justo Santiago, Carlos E. Prada

    Intracardiac rhabdomyoma is the most common primary cardiac tumor in children. Most cases are associated with tuberous sclerosis complex (TSC). Most of them are asymptomatic in the neonate and do not require treatment. However, some develop cardiovascular symptoms such as arrhythmias, heart failure, and ventricular inflow/outflow tract obstruction in the neonatal period with early death. Many of these tumors are not candidates for surgical resection and medical management is limited. Treatment with mammalian target of rapamycin (mTOR) inhibitor is currently approved for the management of central nervous tumors and angiomyolipoma in TSC. Two patients with malignant arrhythmias related to nonsurgical multiple rhabdomyomas associated with TSC who were successfully treated with an mTOR inhibitor were described. Everolimus therapy showed significant regression of rhabdomyomas with rapid improvement of arrhythmias and heart failure prior to tumor shrinkage.